Creo Medical Group PLC Video abstract published endorsing Speedboat
August 03 2020 - 1:00AM
RNS Non-Regulatory
TIDMCREO
Creo Medical Group PLC
03 August 2020
Creo Medical Group plc
("Creo" or the "Company")
Video abstract published endorsing Speedboat procedure
Creo Medical Group plc (AIM: CREO), the medical device company,
focused on the emerging field of surgical endoscopy, announces that
early experience of the Company's Speedboat(TM) Inject device has
shown that it is feasible for performing peroral endoscopic myotomy
(POEM) with a good safety profile. The abstract was authored by
experts in the field of Gastrointestinal ('GI') therapeutics
endoscopy, including Dr. Amit Maydeo an internationally renowned
Gastroenterologist and endoscopy expert, known for his pioneering
efforts on therapeutic endoscopy.
The main advantages of using Speedboat Inject were highlighted
as reducing the risk of injury to the mucosa by the orientation of
the hull and use of bipolar radiofrequency, which then aided quick
tissue healing and resulted in quicker post-procedural recovery.
Speedboat also reduced the overall procedure time, as no device
changes were needed for bleeding vessels.
The video abstract, published via an open access content
publisher, Thieme Group titled: 'Feasibility of Speedboat RS2 with
bipolar radiofrequency energy for peroral endoscopic myotomy in
patients with achalasia (with video)' can be viewed online
here:
https://www.thieme-connect.com/products/ejournals/html/10.1055/a-1165-0087
Dr Amit Maydeo, Chairman & Chief of Gastroenterology &
Therapeutic Endoscopy at the Baldota Institute of Digestive
Sciences at the Global hospital in Mumbai, commented: "Our center
has been performing POEM for almost a decade and diverticular POEM,
and the advent of Speedboat Inject, has certainly opened up new
avenues in submucosal endoscopy. We feel the advanced technology of
Speedboat overcome many of the problems faced in routine third
space procedures. Although the economics of it currently remain
unexplored, the device certainly looks to make a huge impact in
terms of its advantages over currently existing standard
accessories in POEM."
Craig Gulliford, Chief Executive Officer, commented: "We are
pleased to see the Speedboat device included in another video
abstract as more and more physicians are trained up and performing
procedures globally."
Enquires:
Creo Medical Group plc www.creomedical.com
Richard Rees (CFO) +44 (0)1291 606 005
Cenkos Securities plc +44 (0)20 7397 8900
Stephen Keys / Cameron MacRitchie
(NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0)7980 541 893 / +44 (0)7584
391 303
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and RF energy to surgical endoscopy. Creo has
developed CROMA, an electrosurgical Advanced Energy Platform that
combines bipolar radiofrequency for precise localised cutting and
microwave for controlled coagulation. This technology provides
clinicians with flexible, accurate and controlled surgical
solutions.
The Company's strategy is to bring its CROMA Advanced Energy
Platform powered by its unique full spectrum kamaptive technology
to market, enabling a suite of medical devices which the Company
has designed, initially for the emerging field of GI therapeutic
endoscopy, an area with high unmet needs. The CROMA Advanced Energy
platform will be developed further for bronchoscopy and laparoscopy
procedures. The Company believes its technology can impact the
landscape of surgery and endoscopy by providing a safer,
less-invasive and more cost-efficient option of treatment. An
overview of the Creo Medical device technology portfolio can be
seen here:
https://www.rns-pdf.londonstockexchange.com/rns/8918P_1-2020-6-14.pdf
For more information about Creo Medical please see our website,
www.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAKKBBDKBKBCFK
(END) Dow Jones Newswires
August 03, 2020 02:00 ET (06:00 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024